Biosyent (TSXV:RX) Net Change in Cash : C$0.12 Mil (TTM As of Dec. 2023)

View and export this data going back to 1979. Start your Free Trial

What is Biosyent Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Biosyent's Net Change in Cash for the three months ended in Dec. 2023 was C$-1.68 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.12 Mil.

Biosyent Net Change in Cash Historical Data

The historical data trend for Biosyent's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Net Change in Cash Chart

Biosyent Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-3.39

6.85

-2.26

-10.17

0.12

Biosyent Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-0.34	-1.45	2.88	0.37	-1.68

Biosyent Net Change in Cash Calculation

Biosyent's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	5.055	+	0.884	+	-5.785	+	-0.034
	=	0.12

Biosyent's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0.675 + -0.917 + -1.287 + -0.152

= -1.68

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosyent Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Biosyent's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent (TSXV:RX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Net Change in Cash

Comparable Companies

XCNQ:FFNT XCNQ:GRIN XCNQ:INNO TSXV:LOVE XCNQ:TIUM.U XCNQ:GDNS TSX:HLS TSXV:ZYUS XCNQ:ACRG.A.U XCNQ:CXXI ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ

Traded in Other Exchanges

BIOYF:USA

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (TSXV:RX) Headlines

No Headlines